Philip Morris International : Our transformation

In January 2018, we presented information related to the modified risk tobacco product applications (MRTPAs) for our heated tobacco product before the Tobacco Products Scientific Advisory Committee at the U.S. Food and Drug Administration (FDA).

During the two-day presentation, we answered the committee's questions on our research, which suggested that our heated tobacco product was a much better choice for adults who would otherwise continue smoking.

In total, we submitted more than one million pages of documentation related to scientific findings to support our MRTPAs, which, among other things, included aerosol chemistry, non-clinical data, clinical data, consumers studies, and independent studies.

This data package, along with the submissions made in public hearings, was the result of many years of research and development, carried out by hundreds of world-class scientists, engineers, and technicians as part of our rigorous assessment program.